Table 5.
All-cause mortality by statin use after and before ADT in a cohort of prostate cancer patients treated with ADT.
| Statin use after ADT | Statin use before ADT | |||||
|---|---|---|---|---|---|---|
| Participants/deaths | Age-adjusted | Multivariable adjusted | Participants/deaths | Age-adjusted | Multivariable adjusted | |
| HR (95% CI) | HR (95% CI)* | HR (95% CI) | HR (95% CI)* | |||
| None | 2695/1226 | Reference | Reference | 2904/1347 | Reference | Reference |
| Any | 1733/701 | 0.79 (0.72–0.88) | 0.84 (0.76–0.93) | 1524/580 | 1.09 (0.99–1.20) | 1.13 (1.02–1.25) |
| Amount of statin use (DDD) | ||||||
| First tertile** | 574/402 | 0.81 (0.66–1.00) | 0.84 (0.68–1.04) | 508/222 | 1.10 (0.95–1.26) | 1.17 (1.02–1.36) |
| Second tertile | 572/207 | 0.70 (0.61–0.80) | 0.71 (0.62–0.82) | 510/192 | 1.06 (0.91–1.24) | 1.08 (0.93–1.26) |
| Third tertile | 575/83 | 0.58 (0.49–0.68) | 0.61 (0.51–0.71) | 506/166 | 1.11 (0.94–1.30) | 1.12 (0.95–1.32) |
*Calculated using Cox regression with adjustment for age, tumor risk group, randomization group, use of other medication (antidiabetic and antihypertensive drugs, NSAIDs), and whether participants received radiation therapy in addition to ADT.
**Tertiles were defined as follows for statin use after/before ADT: first tertile below 92/120 DDD/year; Second tertile 92-210/120-200; third tertile above 210/200.